At this month’s chat, the #gyncsm community discussed gynecologic cancer research presented at the #SGOmtg and #ASCO23 meetings. We had eleven participants and you may find the transcript HERE and additional analytics HERE.
Below are some responses to our topic questions.
T1: What #SGOMtg presentations did you find most interesting? [Acronym buster: SGO = Society of Gynecologic Oncology]
- SGO mtg round-up from @CancerNetwrk https://www.cancernetwork.com/conference/sgo
- @Stigetta did an excellent job highlighting SGO mtg research https://ocrahope.org/news/highlights-2023-annual-meeting-of-the-society-of-gynecologic-oncology-sgo/
- I found the Pembrolizumab versus Placebo in Addition to Carboplatin and Paclitaxel for Measurable Stage 3 or 4a, Stage 4b or recurrent Endometrial Cancer : Phase 3 NRG GYO18 Study (Keynote 868) study extended survival most interesting. Median Prog free survival 13 months Pembro versus 8 month survival
- There was also the Ruby Trial at #SGOmtg this tweet talks about both. https://twitter.com/eugeniagirda/status/1640481843664265222?s=61
- @womenofteal also covered #SGOMtg on her blog https://womenofteal.blogspot.com/search?q=SGO
T2: Which #ASCO23 studies do you think may be of most interest to patients? [Acronym buster: ASCO = American Society of Clinical Oncology]
- I found this @CancerNetwrk Gyn Cancer round-up page highlighted the main #ASCO23 studies for #gyncsm https://www.cancernetwork.com/clinical/gynecologic-cancer
- The Shape trial for Cervical cancer: phase III trial comparing radical hysterectomy and pelvic node dissection (RH) vs simple hysterectomy and pelvic node dissection (SH) in patients with low-risk early-stage cervical cancer (LRESCC) : fewer side effect w/ simple
- Here's @womenofteal coverage of #ASCO23 https://womenofteal.blogspot.com/search?q=ASCO23&max-results=20&by-date=true
- Lots of discussions on Antibody drug conjugates at #ASCO23 eye toxicities with ADC’s can be handled with steroids. https://twitter.com/womenofteal/status/1664752857885581314?s=61
T3: In the last year, have there been any practice-changing gyn cancer studies patients should know about? (cervical, endometrial/uterine, ovarian. vaginal, vulvar, or other)
- The Future of Endometrial Cancer Treatment Based on Practice-Changing SGO Abstracts https://www.targetedonc.com/view/the-future-of-endometrial-cancer-treatment-based-on-practice-changing-sgo-abstracts via @targetedonc
- T-DXd May be ‘Practice Changing’ in HER2+ Gynecologic Cancers https://www.cancernetwork.com/view/t-dxd-may-be-practice-changing-in-her2-gynecologic-cancers via @CancerNetwrk
- Cervical Cancer OS from Keynote 826 https://twitter.com/ShannonWestin/status/1665088788157063172
T4: What are some of the "hot topics" in gynecologic cancer research currently?
- For me, from what was reported at SGO/ASCO, antibody drug conjugates and immunotherapies were the hot topics.
- Cancer Glossary via @theNCI antibody-drug conjugate https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate
- It feels like we've been talking about targeted therapies and immunotherapy for years, but research is a long game and there are more studies each year on applying these newer modalities to gyn cancers. Here's to these staying on the hot topic lis
- The best practices for PARP use in OC is an important discussion too. https://twitter.com/womenofteal/status/1679290551173103616
- hot topic: Radical hysterectomy and Cervical cancer: SHAPE Trial https://dailynews.ascopubs.org/do/shape-trial-radical-hysterectomy-may-not-needed-early-stage-low-risk-cervical-cancer
T5: Both #ASCO23 and #SGOmtg held sessions on disparity and equity in cancer care. What was highlighted and how can we work to decrease disparities in gynecologic cancer care?
- We can point out all the voices that are missing from conversations.
- It also feels like we've been talking about disparity and equity for years, but I do see more and more studies taking deep dives and it is great to see gyn-specific studies that are fully about disparities or at least have incorporated it into the research. #gyncsm
- Disparity and Equity are complicated to study, but it is entirely possible to not only study but design practical interventions to address. It can seem daunting but when we include more voices we can go far
- Should we treat Pacific Islanders the same as Asian population? https://twitter.com/dholakiamd/status/1640733888988213258
T6: Cancer drug shortages were highlighted at both #SGOMtg and #ASCO23. What resources for health care providers and patients are available?
- T6 @SGO_org has been working hard to highlight the impact of shortages on patients with the Congress and the public https://www.sgo.org/news/drugshortages5/
- @ASCO Drug Shortages Resource Page https://old-prod.asco.org/practice-patients/practice-support/drug-shortages
Note there is no #gyncsm chat in August. Stay tuned for information about our next chat which will be held in September during Gynecologic Cancer Awareness Month / Ovarian Cancer Awareness Month.
See you in September,
Dee and Christina
Co-Moderators
